revatio sildenafil citrate 10 mg/12.5 ml solution for injection vial
viatris pty ltd - sildenafil citrate, quantity: 14.05 mg (equivalent: sildenafil, qty 10 mg) - injection, solution - excipient ingredients: glucose monohydrate; water for injections - oral revatio is for the treatment of patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.,revatio solution for injection is for the treatment of adult patients with pulmonary arterial hypertension who are currently prescribed oral revatio and who are temporarily unable to take oral therapy, but are otherwise clinically and haemodynamically stable.,the efficacy of revatio has not been evaluated in patients currently on bosentan therapy.
minitran 15 glyceryl trinitrate 15mg/24 hour transdermal drug delivery system, sachet
inova pharmaceuticals (australia) pty ltd - glyceryl trinitrate, quantity: 54 mg - drug delivery system, transdermal - excipient ingredients: ethyl oleate; glyceryl laurate; acrylates/acrylamide copolymer - prevention of chronic stable angina pectoris due to coronary artery disease.
minitran 10 glyceryl trinitrate 10mg/24 hour transdermal drug delivery system, sachet
inova pharmaceuticals (australia) pty ltd - glyceryl trinitrate, quantity: 36 mg - drug delivery system, transdermal - excipient ingredients: ethyl oleate; glyceryl laurate; acrylates/acrylamide copolymer - prevention of chronic stable angina pectoris due to coronary artery disease.
minitran 5 glyceryl trinitrate 5mg/24hour transdermal drug delivery system, sachet
inova pharmaceuticals (australia) pty ltd - glyceryl trinitrate, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: ethyl oleate; glyceryl laurate; acrylates/acrylamide copolymer - prevention of chronic stable angina pectoris due to coronary artery disease.
minitran 10
inova pharmaceuticals (new zealand) limited - glyceryl trinitrate 36mg (as 10mg/24h) - transdermal patch - 10 mg/24h - active: glyceryl trinitrate 36mg (as 10mg/24h) excipient: ethyl oleate glyceryl monolaurate ioa/acm copolymer
minitran 5
inova pharmaceuticals (new zealand) limited - glyceryl trinitrate 18mg (as 5mg /24h) - transdermal patch - 5 mg/24h - active: glyceryl trinitrate 18mg (as 5mg /24h) excipient: ethyl oleate glyceryl monolaurate ioa/acm copolymer
minitran
inova pharmaceuticals australia pty ltd - glyceryl trinitrate -
minitran- nitroglycerin patch
bausch health us, llc - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 9 mg - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product. do not use minitran in patients who are taking phosphodiesterase inhibitors (such as sildenafil, tadalafil, or vardenafil) for erectile dysfunction or pulmonary arterial hypertension. concomitant use can cause severe drops in blood pressure. do not use minitran in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.
minitran 5mg/24 hour transdermal patch
meda pharmaceuticals limited skyway house, parsonage road, takeley, bishop''s stortford, cm22 6pu, united kingdom - glyceryl trinitrate - transdermal patch - glyceryl trinitrate milligram(s) - cardiac therapy
minitran 10mg/24 hour transdermal patch
meda pharmaceuticals limited skyway house, parsonage road, takeley, bishop''s stortford, cm22 6pu, united kingdom - glyceryl trinitrate - transdermal patch - glyceryl trinitrate milligram(s) - cardiac therapy